PharmExec
JUNE 13, 2022
While the pharmaceutical industry has historically lagged behind other industries in the overall shift to programmatic advertising, the pandemic accelerated this transformation to emerging channels like connected TV (CTV).
pharmaphorum
JUNE 13, 2022
Canary Wharf’s bid to become a new hub for the life sciences sector in the UK has been given a boost following the decision by Genomics England to relocate to the development. The organisation – which analyses sequenced genomes for the NHS and helps researchers access and use data to help identify the causes of disease – will “anchor” the new cluster, according to Canary Wharf Group (CWG), which is behind the initiative.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmExec
JUNE 13, 2022
Makar discusses the significance of AstraZeneca’s diabetes and heart failure drug Forxiga (dapagliflozin) for the treatment of chronic kidney disease (CKD).
pharmaphorum
JUNE 13, 2022
Parisa “Risa” Vatanka, PharmD, CTTS, senior director of corporate alliances at the American Pharmacists Association (APhA), tells us about the ideal role of pharmacists in patient care and their effort to gain provider status. . Pharmacists are the most accessible, most frequently visited healthcare providers, but despite their contribution to supporting communities’ health, pharmacists lack provider status recognition to be appropriately compensated for their services. “
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PharmD Live
JUNE 13, 2022
By Ryan Payne, PharmD. Because of the insidious nature of chronic kidney disease, and because most people affected do not have symptoms until the condition becomes advanced, it is sometimes under-recognized by busy healthcare providers. According to the National Kidney Foundation, kidney disease affects an estimated 37 million people in the United States.
pharmaphorum
JUNE 13, 2022
ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase 2 results with camidanlumab tesirine (cami) in relapsed/refractory Hodgkin lymphoma at the EHA annual meeting. In the study, 70% of patients treated with the CD25-targeting ADC had a response to therapy, with 33% of them having a complete response – in other words their cancer went into remission – with a median response time of 13.7 months.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
JUNE 13, 2022
Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US market and chasing down rival drugs from Astellas and Novartis. Data from the QuANTUM-First trial presented at the EHA congress showed that quizartinib more than doubled the median overall survival when added to first-line chemotherapy in patients with newly-diagnosed, FLT3-ITD-positive acute myeloid l
Outsourcing Pharma
JUNE 13, 2022
The patient recruitment solutions company plans to work with the charity to support research and clinical trials through a range of fundraising activities.
pharmaphorum
JUNE 13, 2022
Amylyx Pharmaceuticals’ efforts to bring its amyotrophic lateral sclerosis therapy AMX0035 to market in the US have run into some roadblocks, so an approval by Health Canada is a welcome relief for the biotech. Canada is the first country worldwide to approve the combination of orally active ingredients sodium phenylbutyrate and taurursodiol – as Albrioza – marking Amylyx’ transition from a development-stage to a commercial-stage company.
Outsourcing Pharma
JUNE 13, 2022
An expert from the trial tech company discusses tools that can prove useful for trial teams looking to avoid employee shortages plaguing other industries.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JUNE 13, 2022
SAE Media Group’s 2nd Annual Biosensors for Medical Wearables. *In collaboration with Medical Design Briefs*. 24th – 25th October 2022 | Boston, MA, USA. Sponsored by: Raumedic. [link]. Advances in development and therapeutic applications of on-body sensors. SAE Media Group is proud to present the Biosensors for Medical Wearables Conference, taking place on the 24th – 25th October 2022.
PharmExec
JUNE 13, 2022
Eagle tele-rheumatology joins list of more than 15 physician specialties.
Impact Pharmaceutical Services
JUNE 13, 2022
RESEARCH TRIANGLE PARK, NC: 13 June 2022. Syner-G BioPharma Group (“Syner-G”), a leading provider of consulting services to pharmaceutical and biotechnology clients, today announced that Ron Kraus has joined the company as Chief Executive Officer (CEO). Mr. Kraus has more than 25 years of experience leading life sciences companies, including global responsibility for customer strategy, sales, operations, and various support functions.
PharmExec
JUNE 13, 2022
New accelerator will develop products and solutions with the use of digital, data, and AI.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Impact Pharmaceutical Services
JUNE 13, 2022
RESEARCH TRIANGLE PARK, NC: 13 June 2022 Syner-G BioPharma Group (“Syner-G”), a leading provider of consulting services to pharmaceutical and biotechnology clients, today announced that Ron Kraus has joined the company as Chief Executive Officer (CEO). Mr. Kraus has more than 25 years of experience leading life sciences companies, including global responsibility for customer strategy, […].
PharmExec
JUNE 13, 2022
The new user experience improvements will make it easier for members to discover and interact with relevant products related to their medical specialty.
Pharmaceutical Commerce
JUNE 13, 2022
Will serve as a hub, as company aims for growth in the European region.
PharmExec
JUNE 13, 2022
The former North America President and CEO of Daiichi Sankyo will lead Ascletis' corporate business development and alliance management.
Pharmaceutical Commerce
JUNE 13, 2022
Dominance of a handful of integrated firms “at the center of the US pharmaceutical system,” plus their trade practices, will be reviewed.
PharmExec
JUNE 13, 2022
Brent Palmisano joins Lauren Cohen, who recently joined as vice president of marketing and communications.
Pharma Manufacturing
JUNE 13, 2022
Lacking an established workforce, the nascent cell and gene therapy industry must grow its own talent
PharmExec
JUNE 13, 2022
Doceree ABM empowers healthcare marketers to reach institutional stakeholders and measure account lift.
Pharma Times
JUNE 13, 2022
First-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer and renal cancer
PharmExec
JUNE 13, 2022
Company hires life science veteran Jessica Cao to join management team.
Pharmaceutical Commerce
JUNE 13, 2022
GMP facility allows for an increase in AAV vector production.
Pharma Times
JUNE 13, 2022
It is the first treatment in its class to receive NICE approval for cardiovascular risk reduction
pharmaphorum
JUNE 13, 2022
An analysis of images of the retina harvested from the UK Biobank resource suggests that it may be possible to identify individuals at risk of coronary artery disease by examining the pattern of blood vessels in the retina during an eye test. The researchers combined data from the branching of blood vessels in the retina with genetic data in the study, which was presented today at the European Society of Human Genetics.
Expert insights. Personalized for you.
118 
Let's personalize your content